enGene Inc. Warrants

NASDAQ: ENGNW · Real-Time Price · USD
0.70
-0.02 (-2.78%)
At close: Apr 28, 2025, 2:28 PM
-2.78%
Bid n/a
Market Cap 35.69M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) n/a
PE Ratio (ttm) n/a
Forward PE n/a
Analyst n/a
Ask n/a
Volume 1
Avg. Volume (20D) 7,742.635
Open 0.71
Previous Close 0.72
Day's Range 0.70 - 0.71
52-Week Range 0.70 - 0.71
Beta -0.37

About ENGNW

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calm...

Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 56
Stock Exchange NASDAQ
Ticker Symbol ENGNW
Full Company Profile

Advertisement

No News article available yet